SARS-CoV-2 and COVID-19 Research

The paper develops fluorescent protein fusions to study receptor binding of viral envelope proteins in cells.

The paper analyzes antibody neutralization data from multiple countries to assess how prior exposure to SARS-CoV-2 variants affects neutralization profiles of BA.2.86 and its descendants.

This study investigates how N343 glycosylation affects the structure and co-receptor binding of the SARS-CoV-2 S RBD across variants of concern using molecular dynamics simulations.

PRIEST predicts SARS-CoV-2 mutations with immune escape potential using temporal evolutionary data and deep learning.

The paper identifies that the human microbiota contributes to SARS-CoV-2 mutations by replicating bacterial mRNAs with advantageous mutations, leading to chimeric RNAs and altered viral properties.

This paper develops a Bayesian weighted scheme to predict SARS-CoV lineage evolution and demonstrates its retrospective application to anticipate SARS-CoV-2 emergence from SARS-CoV-1.

The paper uses M13 phage display to identify SARS-CoV-2 neutralizing peptides, finding three candidates with both binding and neutralizing capacity.

This study investigates SARS-CoV-2 neutralising antibodies in sheep exposed to the virus, finding partial neutralisation against Wuhan and Delta variants but escape in Omicron variants, suggesting cross-species transmission risks.

This study shows that immune imprinting from prior Wuhan-Hu-1 spike exposure persists after XBB.1.5 vaccine booster, with neutralizing antibodies dominated by pre-existing memory B cells.

This paper develops scalable machine learning methods to identify significant SARS-CoV-2 lineages from genomic data, offering a complementary approach to traditional phylogenetic analysis.

This study characterizes SARS-CoV-2 variants XBB and BA.2.86/JN.1, finding they show increased fitness and antibody evasion while maintaining antiviral sensitivity.

The paper identifies ligands binding to the SARS-CoV-2 nsp10-16 complex using X-ray crystallography and reports their structures, providing insights for drug discovery.

This study investigates ligand dissociation from the SARS-CoV-2 spike glycoprotein using simulations, revealing two unbinding pathways and key residues involved in ligand binding and ACE2 interaction.

The paper examines how different SARS-CoV-2 variants bind to the human ACE2 receptor, identifying regions of ACE2 involved in binding and suggesting multiple binding sites contribute to interaction.

The paper investigates the interaction between SARS-CoV-2 spike RBD and membrane-bound ACE2, showing rapid internalization and ACE2 downregulation, with variant-specific differences in binding dependencies.

The paper analyzes SARS-CoV-2 genomic variants from hospitalized severe pneumonia patients in Mexico, identifying mutations associated with increased mortality.

This study shows ORF8 suppresses viral particle production by interacting with Spike and causing Golgi fragmentation, supporting evolutionary pressure to delete ORF8 in SARS-CoV-2 variants.

This study investigates enzalutamide's antiviral effects against seasonal coronaviruses and identifies differences in viral-androgen signaling interactions between HCoV-229E and HCoV-OC43.

This paper reviews immune epitopes of SARS-CoV-2 Spike protein and discusses their implications for universal vaccine development.

This study develops bispecific antibodies that restore effectiveness against SARS-CoV-2 variants resistant to existing antibodies by combining non-neutralizing antibodies targeting different epitopes.

This study shows that temperature affects SARS-CoV-2 spike fusogenicity and evolution, with higher temperatures increasing fusion and specific mutations showing temperature-dependent effects.

The paper investigates tissue-specific metabolic reprogramming and gut dysbiosis in hamsters infected with SARS-CoV-2 variants, revealing differences in viremia, metabolic responses, and microbiota composition between delta and omicron variants.

This study shows that the N-terminal fragment of α-dystroglycan blocks SARS-CoV-2 and other enveloped viruses in cell culture and animal models.

XBB.1.5 monovalent mRNA vaccine booster significantly increases neutralizing antibodies against multiple SARS-CoV-2 variants in both uninfected and previously infected individuals.

This study shows that prior malaria exposure in K18-hACE2 mice reduces SARS-CoV-2 mortality without affecting lung viral load.

This study uses AlphaFold2 and molecular dynamics to analyze the structure, dynamics, and binding of SARS-CoV-2 Omicron BA.2.86 spike protein with ACE2 and antibodies, revealing key mutations that enhance immune evasion and ACE2 binding.

This study characterizes SARS-CoV-2 BA.5 variants in H11-K18 hACE2 golden hamsters, showing disease progression and severity similar to human infections, supporting the model's utility for research.

The paper describes open data sharing, analysis tools, and lessons learned from the European COVID-19 Data Platform's SARS-CoV-2 data collection and analysis efforts.

This study evaluates immune escape and replicative capacity of Omicron variants in human airway epithelial cells and sera from diverse immunological backgrounds.

This paper develops a multi-antigen mRNA/LNP-based pan-CoV vaccine that provides cross-protective immunity against multiple SARS-CoV-2 variants in a hamster model.